The Magazine for Sleep Professionals
Thursday, March 19, 2026
Inspire Medical Systems, Inc. announced that two leading physicians in sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire as Vice President and senior Medical Director, effective April 21 and June 2, respectively. “Dr. […]
While continuous positive airway pressure (CPAP) is still the gold standard treatment for obstructive sleep apnea (OSA), it is well-established that many patients struggle with long-term adherence and tolerance.1 The literature indicates that CPAP non-compliance rates remain as high as 34% with little improvement over the last two decades.2 As […]
Inspire Medical Systems, Inc. announced today the publication of the reimbursement of Inspire therapy in France. “We are thrilled to offer our clinically proven treatment option for moderate to severe OSA to patients and physicians in France,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire. “Inspire therapy is […]
Today, Inspire Medical Systems, Inc. announced certain preliminary, unaudited results for the fourth quarter and full year that ended December 31, 2023, and provided its initial full-year 2024 guidance. Preliminary, Unaudited Fourth Quarter and Full Year 2023 Revenue and Recent Business Highlights Revenue for the fourth quarter of 2023 is […]
Inspire Medical Systems, Inc. has reported financial results for the quarter ended September 30, 2023. Recent Business Highlights Generated revenue of $153.3 million in the third quarter of 2023, a 40% increase over the same quarter last year Achieved gross margin of 84.1% in the third quarter of 2023 Reduced loss […]
Inspire Medical Systems, Inc. announced that it has received approval from the Food and Drug Administration (FDA) on an expanded indication. The update includes an increase on the upper limit of the Apnea-Hypopnea Index (AHI) to 100 events per hour from 65 and raises the Body Mass Index (BMI) warning […]
Inspire Medical Systems, Inc. announced today that it has received approval from the Food and Drug Administration (FDA) to offer Inspire therapy to pediatric patients with Down syndrome. “Since our first FDA approval in 2014, the research team at Mass Eye and Ear, led by Dr. Christopher Hartnick, have pioneered […]
By RTSleepWorld Staff Since the April 2022 press release announcing their investment by Inspire Medical Systems, Ognomy, the telemedicine platform, and app, has grown and continues to innovate towards its mission of democratizing access to expert sleep apnea care. Ognomy is an easy and effective way for patients to consult […]
Inspire Medical Systems, Inc. announced that the United States Food and Drug Administration (FDA) has approved additional magnetic resonance imaging (MRI) scan conditions for use with Inspire therapy. This full-body MRI approval expands the Inspire use labeling that previously allowed only head, neck, and extremity MRI scans. Most importantly, this […]
Inspire Medical Systems, Inc. (“Inspire”) reported equity investments in two private companies, EnsoData, Inc. in Madison, WI, and Ognomy Inc. in Buffalo, NY. EnsoData increases sleep lab capacity and efficiency with their FDA-approved sleep study analysis platform, EnsoSleep. Using waveform Artificial Intelligence (AI), EnsoSleep automates the scoring and analysis of […]
